These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23935828)

  • 1. The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.
    Goebel S; Li Z; Vogelmann J; Holthoff HP; Degen H; Hermann DM; Gawaz M; Ungerer M; Münch G
    PLoS One; 2013; 8(7):e66960. PubMed ID: 23935828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPVI‑Fc‑PEG improves cerebral infarct volume and cerebral thrombosis in mouse model with cerebral thrombosis.
    Wufuer Y; Shan X; Sailike M; Adilaimu K; Ma S; Wang H
    Mol Med Rep; 2017 Nov; 16(5):7561-7568. PubMed ID: 28944903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.
    Reimann A; Li Z; Goebel S; Fassbender J; Holthoff HP; Gawaz M; Münch G; Ungerer M
    Heart Int; 2016; 11(1):e10-e16. PubMed ID: 27924212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times.
    Ungerer M; Li Z; Baumgartner C; Goebel S; Vogelmann J; Holthoff HP; Gawaz M; Münch G
    PLoS One; 2013; 8(8):e71193. PubMed ID: 23951109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
    Dhanesha N; Prakash P; Doddapattar P; Khanna I; Pollpeter MJ; Nayak MK; Staber JM; Chauhan AK
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1829-37. PubMed ID: 27444201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial.
    Schüpke S; Hein-Rothweiler R; Mayer K; Janisch M; Sibbing D; Ndrepepa G; Hilz R; Laugwitz KL; Bernlochner I; Gschwendtner S; Kupka D; Gori T; Zeiher AM; Schunkert H; Massberg S; Kastrati A;
    Thromb Haemost; 2019 Sep; 119(9):1539-1545. PubMed ID: 31226721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Platelet GPVI Plus rt-PA Administration but Not α2β1-Mediated Collagen Binding Protects against Ischemic Brain Damage in Mice.
    Schuhmann MK; Kraft P; Bieber M; Kollikowski AM; Schulze H; Nieswandt B; Pham M; Stegner D; Stoll G
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo.
    Massberg S; Konrad I; Bültmann A; Schulz C; Münch G; Peluso M; Lorenz M; Schneider S; Besta F; Müller I; Hu B; Langer H; Kremmer E; Rudelius M; Heinzmann U; Ungerer M; Gawaz M
    FASEB J; 2004 Feb; 18(2):397-9. PubMed ID: 14656994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type.
    Jooss NJ; Henskens YMC; Watson SP; Farndale RW; Gawaz MP; Jandrot-Perrus M; Poulter NS; Heemskerk JWM
    Thromb Haemost; 2023 Jun; 123(6):597-612. PubMed ID: 36807826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.
    Mayer K; Hein-Rothweiler R; Schüpke S; Janisch M; Bernlochner I; Ndrepepa G; Sibbing D; Gori T; Borst O; Holdenrieder S; Kupka D; Petzold T; Bradaric C; Okrojek R; Leistner DM; Trippel TD; Münzel T; Landmesser U; Pieske B; Zeiher AM; Gawaz MP; Hapfelmeier A; Laugwitz KL; Schunkert H; Kastrati A; Massberg S
    JAMA Cardiol; 2021 Jul; 6(7):753-761. PubMed ID: 33787834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
    Berny-Lang MA; Hurst S; Tucker EI; Pelc LA; Wang RK; Hurn PD; Di Cera E; McCarty OJ; Gruber A
    Stroke; 2011 Jun; 42(6):1736-41. PubMed ID: 21512172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial.
    Uphaus T; Richards T; Weimar C; Neugebauer H; Poli S; Weissenborn K; Imray C; Michalski D; Rashid H; Loftus I; Rummey C; Ritter M; Hauser TK; Münch G; Gröschel K; Poppert H
    Stroke; 2022 Sep; 53(9):2718-2729. PubMed ID: 35695006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice.
    Grüner S; Prostredna M; Koch M; Miura Y; Schulte V; Jung SM; Moroi M; Nieswandt B
    Blood; 2005 Feb; 105(4):1492-9. PubMed ID: 15507524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiplatelet agent revacept prevents the increase of systemic thromboxane A
    Alberti S; Zhang Q; D'Agostino I; Bruno A; Tacconelli S; Contursi A; Guarnieri S; Dovizio M; Falcone L; Ballerini P; Münch G; Yu Y; Patrignani P
    Sci Rep; 2020 Dec; 10(1):21420. PubMed ID: 33293599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
    Hoylaerts MF
    Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells.
    Dovizio M; Maier TJ; Alberti S; Di Francesco L; Marcantoni E; Münch G; John CM; Suess B; Sgambato A; Steinhilber D; Patrignani P
    Mol Pharmacol; 2013 Jul; 84(1):25-40. PubMed ID: 23580446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Vimentin/VWF (von Willebrand Factor) Interaction Contributes to VWF String Formation and Stroke Pathology.
    Fasipe TA; Hong SH; Da Q; Valladolid C; Lahey MT; Richards LM; Dunn AK; Cruz MA; Marrelli SP
    Stroke; 2018 Oct; 49(10):2536-2540. PubMed ID: 30355099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.